The interpretation and review of urothelial carcinoma, 2023 EMSO

VernacularTitle:2023 ESMO尿路上皮癌精粹解读
Author: Yige BAO ¹ ; Junru CHEN ; Hao ZENG ; Qiang WEI
Author Information

1. 四川大学华西医院泌尿外科　四川大学华西医院泌尿外科研究所，成都　610041
Keywords: Urothelial carcinoma; Non-muscle invasive bladder cancer; Muscle-invasive bladder cancer; Oncotherapy; European Society for Medical Oncology (ESMO)
From: Chinese Journal of Urology 2023;44(12):889-892
CountryChina
Language:Chinese
Abstract: We present a summary of important research in the field of urothelial carcinoma presented at the 2023 European Society for Medical Oncology (ESMO) conference. A total of 53 studies related to urothelial carcinoma were reported, including 6 late-breaking abstract, 7 oral presentations, and 40 poster presentations. Several new treatment options were reported in the non-muscle invasive bladder cancer (NMIBC) field, providing more choices for bacillus Calmette-Guerin (BCG) failing patients. For perioperative systemic treatment of muscle-invasive bladder cancer (MIBC), studies further explored various adaptation of neoadjuvant therapy strategies. For metastatic urothelial carcinoma (mUC), the data on CheckMate-901 and EV-302 studies provided thoughts on first-line treatment options. These studies provide important guidance for clinical practice in the field of urothelial carcinoma.